Who we are

Since 1929, we have worked to be the fundamental link between the laboratory and everyday life, developing, producing, and distributing essential health solutions — from the most critical and specialized treatments to prevention and well-being — in every corner of the world.

At REIG JOFRE, our strategic vision is closely aligned with our mission to simplify and universalize essential health in an increasingly complex world.
Based on our deep understanding of people’s fundamental health needs, we are committed to constant innovation and international expansion to bring essential solutions to more people around the world.

This strategic direction translates into a focus on innovation and technology, with an ambition to internationalize our solutions.

We strive not only to be leaders in healthcare, but also to contribute to economic development and create qualified employment in Europe.

The validation and acceleration of emerging technologies in the post–COVID-19 era — such as gene therapy and mRNA technology during the pandemic — inspire us to make our industrial expertise and know-how available on a large scale for these innovations.

We focus on maximizing the efficiency of our plants through the use of our state-of-the-art facilities. In addition, we continue along our path of international expansion, broadening our geographic reach while consolidating our business in existing markets.

As part of our commitment to innovation and the universalization of health, at REIG JOFRE we partner with industry leaders to drive pioneering projects, develop cutting-edge therapeutic solutions, and expand access to innovative treatments for patients around the world.

As an example of this and as a result of our collaboration with the ecosystem, in 2018 we created a Joint Venture with LeanBio, Syna Therapeutics, to develop and produce high-therapeutic-value biosimilar biotechnological products based on complex molecules such as proteins and antibodies.

We also maintain a collaboration agreement with Archivel Farma, whose aim is to establish a GMP-compliant pilot plant for advanced cell therapies that require small-batch production and highly specific and complex know-how.

International expansion is a key and indispensable component in achieving our goal of universalizing essential health solutions for as many people as possible around the world. Our entry into more than eight countries through our own commercial teams or through distribution and licensing agreements has driven our growth, enabling us to consolidate our presence in over 70 countries.

REIG JOFRE has a deep and long-standing commitment to building industrial capacity in Europe and promoting an innovative industry capable of developing and producing essential molecules for health — not only for today’s therapeutic medicines but also for the most advanced forms of medicine and the health challenges of tomorrow.
We dedicate our production centers to specialized, high-value pharmaceutical technologies with a direct impact on health. We work to provide the highest production quality and exceptional service to our commercial units and to our customers, whether distributors or licensees.

In addition, we collaborate with third-party projects to bring R&D to its fullest expression in commercial products, also with the goal of developing innovative capacity that fosters specialized industrial growth in our country. We are focused on the continuous improvement of industrial efficiency and the reduction of natural resource consumption, investing in our plants as a strategic pillar for maintaining quality and increasing production efficiency.